Karyopharm Therapeutics (KPTI) Misses Q2 EPS by 432c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($4.32). Revenue for the quarter came in at $37.93 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Jefferies Financial Group (JEF) Tops Q3 EPS by 8c
• Faraday Future plans robotics spinoff with AIxC at $200M valuation
• Viking and NorthStar Earth & Space to merge on NYSE American